
Opinion|Videos|March 27, 2025
Navigating Biologic Treatment Selection in Psoriasis and Psoriatic Arthritis
Panelists discuss how selecting among the numerous approved biologic therapies for psoriasis requires a personalized approach that weighs factors such as efficacy data, safety profiles, comorbidities, insurance coverage, and administration preferences, with patient preferences playing a crucial role in the decision-making process, as involving patients in treatment selection enhances medication adherence and satisfaction and ultimately improves long-term outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- With so many biologics approved for psoriasis treatment, how do you navigate choosing a biologic therapy for your patients?
- What’s the role of patient preference?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Combination Therapy, Adherence, and Access: A PAH Expert Roundtable
2
Allergists Debate Newer Nonsteroidal Topicals for Atopic Dermatitis
3
CaRi-Heart Receives FDA De Novo Authorization for Coronary Inflammation
4
Ritlecitinib Improves Repigmentation in Nonsegmental Vitiligo Phase 3 Data
5











































































